Get the Stockscreener App
0.4044
6.17%
-0.0266
Pre-market:
.40
-0.0044
-1.09%
Nexalin Technology Inc stock is traded at $0.4044, with a volume of 132.08K.
It is down -6.17% in the last 24 hours and up +18.07% over the past month.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
See More
Previous Close:
$0.431
Open:
$0.42
24h Volume:
132.08K
Relative Volume:
0.17
Market Cap:
$8.71M
Revenue:
$275.60K
Net Income/Loss:
$-8.33M
P/E Ratio:
-0.8755
EPS:
-0.4619
Net Cash Flow:
$-5.40M
1W Performance:
-19.36%
1M Performance:
+18.07%
6M Performance:
-50.68%
1Y Performance:
-64.83%
1-Day Range:
$0.401
$0.43
1-Week Range:
$0.401
$0.53
52-Week Range:
$0.305
$2.00
Nexalin Technology Inc Stock (NXL) Company Profile
Name
Nexalin Technology Inc
Sector
Industry
Phone
(832) 260-0222
Address
1776 YORKTOWN, HOUSTON
Compare NXL vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NXL
Nexalin Technology Inc
|
0.4044 | 8.71M | 275.60K | -8.33M | -5.40M | -0.4619 |
ABT
Abbott Laboratories
|
88.67 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.94 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.38 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
46.76 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.28 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Nexalin Technology Inc Stock (NXL) Latest News
Exclusive: Nexalin Brazil trial shows benefits across anxiety, sleep and quality of life - MSN
Nexalin reports positive results from anxiety disorder trial By Investing.com - Investing.com Nigeria
NXL Should I Buy - Intellectia AI
EXCLUSIVE: Nexalin Brazil Trial Shows Benefits Across Anxiety, Sleep And Quality Of Life - Sahm
Nexalin Technology, Inc. (NXL) stock price, news, quote and history - Yahoo Finance Australia
Nexalin Technology Q1 2026 Earnings: Wider-than-Expected Loss but Stock Gains 2%ROA Comparison - newsline.com
NXL Q1 2026 Earnings: EPS Misses Estimates, Stock Gains Despite Wider LossEarnings Surprise Score - newsline.com
Nexalin reports positive clinical trial results for anxiety and insomnia - grafa.com
Nexalin reports positive results from anxiety disorder trial - Investing.com UK
Nexalin Study Shows Strong Anxiety and Depression Response in Brazil Trial - Moomoo
Nexalin Technology, Inc. Reports Successful Clinical Trial Results for Non-Invasive Neurostimulation Treatment of Anxiety and Depression - Quiver Quantitative
Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sale - GlobeNewswire
Nexalin receives U.S. patent for neurostimulation method - Investing.com UK
Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia - markets.businessinsider.com
Nexalin receives U.S. patent for neurostimulation method By Investing.com - Investing.com South Africa
Nexalin Technology Announces Issuance of U.S. Patent - GlobeNewswire
New brain stimulation patent targets anxiety, depression, insomnia - Stock Titan
Nexalin Technology | 8-K: Current report - Moomoo
Nexalin Acquires Digital Health Platform Ahead of FDA Pivotal Trial for Insomnia Treatment - Sleep Review
Nexalin Technology (NXL) Surges 16%: Breakout Potential Above ResistanceValue ETF - The Legal Advocate
Nexalin Technology earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada
Nexalin Technology earnings beat, revenue fell short of estimates - Investing.com
Nexalin Technology Q1 2026 Earnings: EPS Misses Estimates Amidst Narrowing LossesProfit Margin Analysis - The Legal Advocate
Nexalin Technology Inc. (NXL) Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Company Intensifies R&D SpendSegment Revenue Breakdown - newsline.com
Nexalin Technology, Inc.Common Stock (NQ: NXL - The Chronicle-Journal
Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury - Sahm
Nexalin Technology (NXL) Surges 19% as Momentum Builds Toward Key ResistanceWave Equality - The Legal Advocate
Nexalin Technology (NXL) Q1 2026 Profit Slips to $-0.11 — Misses Analyst ForecastsFiscal Year Earnings - The Legal Advocate
House committee directs VA to research brain stimulation for TBI By Investing.com - Investing.com Australia
House committee directs VA to research brain stimulation for TBI - Investing.com
Maxim Group Maintains Nexalin Technology(NXL.US) With Buy Rating, Maintains Target Price $2 - Moomoo
Nexalin Technology Secures Key Neurostimulation Legislative - GlobeNewswire
Nexalin Technology (NXL) Q1 2026 Earnings Miss: EPS $-0.11 vs $-0.10 ExpectedSaaS Earnings Trends - The Legal Advocate
Nexalin Acquires PONM to Expand AI Health Platform - TipRanks
Nexalin Acquires PONM for $1.3 Million in Stock, Adds 24-Month GLV Collaboration - TradingView
Nexalin (NXL) acquires PONM AI health platform in $1.3M stock deal - Stock Titan
Nexalin acquires digital health platform PONM for $1.3M - Investing.com India
Nexalin acquires digital health platform PONM for $1.3M By Investing.com - Investing.com South Africa
Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial - The Manila Times
Nexalin Acquires AI-Integrated Digital Health Platform - GlobeNewswire
Nexalin Technology, Inc. acquired PONM, Inc. from GreenLight Ventures, LLC for $1.3 million. - marketscreener.com
Nexalin Technology (NXL) Trading at $$0.34 — Key Decision Point 2026-05-14Popular Trader Picks - Newser
TradingKey - TradingKey
Number of shareholders of Nexalin Technology, Inc. – NASDAQ:NXL - TradingView
NXL Financials: Income Statement, Balance Sheet & Cash Flow | Nexalin Tech - Stock Titan
Nexalin Technology, Inc. 1Q 2026: Revenue $14.95K, EPS ($0.11) — 10-Q Summary - TradingView
Nexalin Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Nexalin Technology (NXL) Q1 loss, cash burn and Nasdaq bid-price warning - Stock Titan
Peer-Reviewed Neuroimaging Data Supports Nexalin’s Technology for Chronic Insomnia - Sleep Review
Nexalin Technology Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
MSN Money - MSN
Nexalin Technology Inc Stock (NXL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):